Abstract
During more than five decades, pyridinium oximes have been developed as therapeutic agents used in the medical treatment of poisoning with organophosphorus compounds. Their mechanism of action is reactivation of acetylcholinesterase (AChE) inhibited by organophosphorus agents. Organophosphorus compounds (OPC) are used as pesticides and developed as warfare nerve agents such as tabun, soman, sarin, VX and others. Exposure to even small amounts of an OPC can be fatal and death is usually caused by respiratory failure resulting from paralysis of the diaphragm and intercostal muscles, depression of the brain respiratory center, bronchospasm, and excessive bronchial secretions. The mechanism of OPC poisoning involves phosphorylation of the serine hydroxyl group at the active site of AChE leading to the inactivation of this essential enzyme, which has an important role in neurotransmission. AChE inhibition results in the accumulation of acetylcholine at cholinergic receptor sites, producing continuous stimulation of cholinergic fibers throughout the central and peripheral nervous systems. Presently, a combination of an antimuscarinic agent, e.g. atropine, AChE reactivator such as one of the standard pyridinium oximes (pralidoxime, trimedoxime, obidoxime, HI-6) and diazepam has been used for the treatment of organophosphate poisoning in humans. Despite enormous efforts devoted to synthesis and development of new pyridinium oximes as potential antidotes against poisoning with OPC, only four compounds have found their application in human medicine so far. However, they differ in their activity in poisoning with warfare nerve agents and pesticides and there is still no universal broad-spectrum oxime capable of protecting against all known OPC. In this article, we review data on structure-activity relationship of pyridinium oximes and discuss their pharmacological and toxicological significance.
Keywords: Pyridinium oximes, pralidoxime, obidoxime, trimedoxime, HI-6, organophosphorus compounds, acetylcholinesterase, warfare nerve agents
Current Medicinal Chemistry
Title: Pyridinium Oximes as Cholinesterase Reactivators. Structure-Activity Relationship and Efficacy in the Treatment of Poisoning with Organophosphorus Compounds
Volume: 16 Issue: 17
Author(s): Milan Jokanovic and Milica Prostran
Affiliation:
Keywords: Pyridinium oximes, pralidoxime, obidoxime, trimedoxime, HI-6, organophosphorus compounds, acetylcholinesterase, warfare nerve agents
Abstract: During more than five decades, pyridinium oximes have been developed as therapeutic agents used in the medical treatment of poisoning with organophosphorus compounds. Their mechanism of action is reactivation of acetylcholinesterase (AChE) inhibited by organophosphorus agents. Organophosphorus compounds (OPC) are used as pesticides and developed as warfare nerve agents such as tabun, soman, sarin, VX and others. Exposure to even small amounts of an OPC can be fatal and death is usually caused by respiratory failure resulting from paralysis of the diaphragm and intercostal muscles, depression of the brain respiratory center, bronchospasm, and excessive bronchial secretions. The mechanism of OPC poisoning involves phosphorylation of the serine hydroxyl group at the active site of AChE leading to the inactivation of this essential enzyme, which has an important role in neurotransmission. AChE inhibition results in the accumulation of acetylcholine at cholinergic receptor sites, producing continuous stimulation of cholinergic fibers throughout the central and peripheral nervous systems. Presently, a combination of an antimuscarinic agent, e.g. atropine, AChE reactivator such as one of the standard pyridinium oximes (pralidoxime, trimedoxime, obidoxime, HI-6) and diazepam has been used for the treatment of organophosphate poisoning in humans. Despite enormous efforts devoted to synthesis and development of new pyridinium oximes as potential antidotes against poisoning with OPC, only four compounds have found their application in human medicine so far. However, they differ in their activity in poisoning with warfare nerve agents and pesticides and there is still no universal broad-spectrum oxime capable of protecting against all known OPC. In this article, we review data on structure-activity relationship of pyridinium oximes and discuss their pharmacological and toxicological significance.
Export Options
About this article
Cite this article as:
Jokanovic Milan and Prostran Milica, Pyridinium Oximes as Cholinesterase Reactivators. Structure-Activity Relationship and Efficacy in the Treatment of Poisoning with Organophosphorus Compounds, Current Medicinal Chemistry 2009; 16 (17) . https://dx.doi.org/10.2174/092986709788612729
DOI https://dx.doi.org/10.2174/092986709788612729 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Therapy for Inner Ear Diseases
Current Pharmaceutical Design Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Quantum Chemical Approaches: Semiempirical Molecular Orbital and Hybrid Quantum Mechanical/Molecular Mechanical Techniques
Current Pharmaceutical Design Ocular Inflammation and Depression: Ophthalmologists’ Perspective
Current Topics in Medicinal Chemistry The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology EDITORIAL (Thematic Selection: Brain Structural and Functional Effects of Psychopharmacological Treatment in the Major Psychoses)
Current Neuropharmacology The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Coumarin Derivatives in Pharmacotherapy of Alzheimer´s Disease
Current Organic Chemistry Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission
Current Pharmaceutical Design Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Current Topics in Medicinal Chemistry α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Sleep and Circadian Profiles of Bipolar Disorder: From Chronobiology to Novel Therapeutic Strategies
Current Psychiatry Reviews Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Microfluidics for Monitoring Oxidative Stress and Antioxidant Capacity
Current Analytical Chemistry Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Nucleotide Binding Affects Intrinsic Dynamics and Structural Communication in Ras GTPases
Current Pharmaceutical Design